Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL

HOVON CLL Working Group, 28 Sept 2023, In: Blood. 142, 13, p. 1131-1142 12 p.

Research output: Contribution to journal › Article › Academic › peer-review

Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial

Groen, K., Stege, C. A. M., Nasserinejad, K., de Heer, K., van Kampen, R. J. W., Leys, R. B. L., Thielen, N., Westerman, M., Wu, K-L., Ludwig, I., Issa, D. E., Velders, G. A., Vekemans, M-C., Timmers, G-J., de Boer, F., Tick, L. W., Verbrugge, A., Buitenhuis, D., Cunha, S. M., van der Spek, E., & 9 othersde Waal, E. G. M., Sohne, M., Sonneveld, P., Nijhof, I. S., Klein, S. K., van de Donk, N. W. C. J., Levin, M-D., Ypma, P. F. & Zweegman, S., 1 Sept 2023, In: EClinicalMedicine. 63, 102167.

Research output: Contribution to journal › Article › Academic › peer-review

Impact of Comorbidities on Health-related Quality of Life in Nontransplant Eligible Patients with Newly Diagnosed Multiple Myeloma

Bennink, M. C., Stege, C. A. M., Lissenberg-Witte, B. I., Oerlemans, S., Seefat, M. R., Sonneveld, P. & Zweegman, S., 21 Jul 2022, In: HemaSphere. 6, 7, p. E744

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Midostaurin as the Most Likely Cause of Bilateral Adrenal Masses in a Patient with Acute Myeloid Leukemia

Schutte, T., Stege, C. A. M., Smits, M. M., Franssen, L. E., Donker, M. L. & de Leeuw, D. C., 2022, (E-pub ahead of print) In: Clinical drug investigation.

Research output: Contribution to journal › Article › Academic › peer-review